PAREXEL CORPORATE VICE PRESIDENT DR. ALBERTO GRIGNOLO RECEIVES LIFETIME ACHIEVEMENT AWARD FROM GOOD CLINICAL PRACTICE JOURNAL
BOSTON, MA, October 23, 2008 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Alberto Grignolo, Ph.D., Corporate Vice President, PAREXEL Consulting, has received a Lifetime Achievement Award from the Good Clinical Practice Journal (GCPj). Dr. Grignolo was honored at the GCPj Awards ceremony, recognizing excellence in clinical research, which was held October 22, 2008 at the Banqueting House in London, England.
According to Helena Jensen, Publisher of the Good Clinical Practice Journal, “GCPj’s Lifetime Achievement Award is presented to an exceptional individual with a distinguished career in the field of clinical development. We are pleased to honor Dr. Grignolo, who exemplifies dedication to advancing critical aspects of our industry, and whose achievements are especially notable for being consistently forward looking and visionary, from the championing of personalized medicine to his current role on the Executive Committee of the Clinical Trials Transformation Initiative.”
“This honor from the GCPj readership and global clinical development community is for me not an end but rather a new beginning. This recognition is a challenge to inspire others to pursue our shared mission to prevent and cure disease, while continuing to improve the clinical trial enterprise and worldwide standards and practices to benefit patients. Together, through the important work that we do, we can promote innovation, help make personalized therapy a reality in our lifetime, meet urgent medical needs, insist on integrity and ethical behavior, and improve patient access to treatments,” said Dr. Grignolo.
With more than 26 years of experience in regulatory and development strategy, Dr. Alberto Grignolo has helped numerous companies manage business risk by promoting effective regulatory strategies and relationships with regulators. Leading a global team of experts at PAREXEL Consulting, Dr. Grignolo oversees the management of regulatory submissions for clients with Regulatory Authorities worldwide. Dr. Grignolo has been an advocate for progress in personalized drug development, and has helped the industry recognize emerging opportunities to deliver safe and effective medicines to the right patients. Prior to joining PAREXEL, Dr. Grignolo served as President of FIDIA Pharmaceutical Corporation, and held management positions in regulatory affairs at Smith Kline & French Laboratories. He has served as an adviser to the Institute of Medicine of the National Academy of Sciences on human subject protection in clinical trials. He is currently a member of the Executive Committee of the Clinical Trials Transformation Initiative (CTTI). Dr. Grignolo has served as a leader of several industry organizations, including as Chairman of RAPS and on the Board of Directors for DIA. Dr. Grignolo holds a Ph.D. in Psychology from the University of North Carolina at Chapel Hill and a B.S. degree from Duke University. He completed postdoctoral work in neuropharmacology at Duke University Medical Center. He is currently Adjunct Associate Professor at the Massachusetts College of Pharmacy and Health Sciences.
Good Clinical Practice Journal (GCPj) (www.gcpj.com) addresses the regulatory, strategic, and clinical issues that directly impact clinical studies globally.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations throughout 52 countries around the world, and has approximately 8,800 employees. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations throughout 52 countries around the world, and has approximately 8,800 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including ClinPhone; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008 as filed with the SEC on August 28, 2008, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
Related Contacts
Jennifer Baird
Senior Director of Public Relations
PAREXEL International
Tel: +781-434-4409
jennifer.baird@PAREXEL.com
Gene Carozza
PAN Communications
Tel: + 617-502-4300
PAREXEL@pancomm.com